What Karolinska does

Karolinska Development AB (publ), now operating as KDventures, is a publicly listed Swedish life sciences investment company headquartered in Solna. Founded in 2000, the firm provides retail and institutional investors with diversified exposure to a portfolio of 11 biotech and medtech companies, nine of which are listed on Nasdaq. Its stated proposition is to enable investment in future pharmaceutical and medtech companies "without being a specialist in the field and without putting all eggs in the same basket," addressing the information asymmetry that prevents non-specialist investors from accessing early-stage life science opportunities directly.

The company operates as a minority-holding investment vehicle, maintaining equity stakes and active board involvement in portfolio companies spanning therapeutic areas including chronic hepatitis B and D (SVF Vaccines), chronic kidney disease with anemia (Modus Therapeutics), osteogenesis imperfecta (BOOST Pharma), neuropathic pain (PharmNovo), cardiac conditions (AnaCardio), and neurological disorders (Umecrine Cognition). Karolinska Development holds a 33% stake in SVF Vaccines, which is pursuing a reverse acquisition of Novakand Pharma for a Nasdaq First North listing. The firm does not develop products itself; portfolio companies commercialize their own therapeutic candidates and medical technologies through standard pharmaceutical and medtech distribution channels.

KDventures generates economics primarily through changes in portfolio fair value and realized exit proceeds rather than recurring operating revenue, funded in part by equity issuances to public shareholders. Recent capital actions include a SEK 7.5 million follow-on into BOOST Pharma (October 2025), a SEK 202.6 million rights issue of series B shares (January 2026), and a SEK 23.9 million directed share issue (June 2026). The company is led by CEO Viktor Drvota and Chairman Ben Toogood, with a core team of 1-10 employees. No revenue figure is disclosed in available materials.

Name

Karolinska

Legal name

Karolinska Development AB (publ)

Website

https://karolinskadevelopment.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Karolinska Development (now KDventures) is a publicly listed Swedish life sciences investment company that holds minority stakes in 11 biotech and medtech portfolio companies, providing retail and institutional investors diversified exposure to early-stage pharmaceutical and medical technology assets.

Ownership category

akta.pro rank

Headquarters

HQ city

Solna

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Others

Marketing channels2 records

Core offering

Karolinska Development AB (operating as KDventures) is a Swedish life sciences investment company that provides retail and institutional investors with access to a diversified portfolio of early-stage and listed pharmaceutical and medtech companies. The firm invests in, and provides strategic and financial support to, portfolio companies developing therapeutic candidates and medical technologies, enabling investors to gain exposure to life science innovation without requiring specialist expertise.

Product overview

KDventures operates as a life sciences investment company offering a single unified investment platform that provides exposure to a portfolio of 11 life science companies across 9 Nasdaq listings. The company's investment approach focuses on early-stage to established pharmaceutical and medtech companies, with the portfolio including portfolio companies such as Modus Therapeutics (sevuparin for chronic kidney disease with anemia), BOOST Pharma (BT-101 stem cell therapy for osteogenesis imperfecta), SVF Vaccines (SVF-001 immunotherapy for hepatitis B and D), PharmNovo (PN6047 for neuropathic pain), AnaCardio, and Umecrine Cognition (golexanolone). The company also facilitates investment through mechanisms such as rights issues and directed share issuances.

Differentiator

Problem solved

Functional benefit

Products and services

• KDventures Investment Platform

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor.

• Cirio Advokatbyrå ABminorImplementation/ SI/ Consulting PartnerServing as legal adviser for the rights issue transaction.
• Nordic Issuing ABminorImplementation/ SI/ Consulting PartnerServing as issuing agent for the rights issue transaction.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Emerging players

• Kurma Partners: European venture capital firm focused on early- to mid-stage biotech and medtech. Adjacent to KDventures' investment focus, though private and venture-led rather than publicly listed.

Direct peers

• Polar Capital Global Healthcare Trust: UK-listed trust investing in global healthcare equities. Comparable as a publicly traded diversified healthcare/biotech investor with similar end-investor proposition.
• BB Biotech AG: Swiss-listed closed-end fund that invests in a concentrated portfolio of public and private biotech companies. Directly comparable to KDventures as a publicly traded vehicle providing diversified biotech exposure.
• Arix Bioscience plc: London-listed life sciences investment company backing early and growth-stage therapeutic companies. Directly comparable as a publicly traded biotech investment vehicle similar to KDventures.
• Worldwide Healthcare Trust plc: UK-listed investment trust focused on global healthcare equities including biotech and medtech. Comparable in providing listed-vehicle exposure to a diversified life sciences portfolio.
• International Biotechnology Trust plc: UK-listed investment trust providing diversified exposure to global biotech equities. Comparable to KDventures as a long-standing publicly listed biotech investor offering portfolio diversification.
• Syncona Limited: UK-listed life sciences investment trust that builds, holds and supports early-stage biotech companies. Comparable in providing public investors access to a portfolio of clinical-stage therapeutics companies.
• HBM Healthcare Investments AG: Swiss-listed investor focused on private and small-cap public healthcare companies across therapeutics, medtech and diagnostics. Closely mirrors KDventures' model of holding minority stakes across a diversified life sciences portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Karolinska_Dev
• LinkedInlinkedin.com/company/karolinska-development

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments32 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karolinska